Published in final edited form as:

Bioconj Chem. 2019 July 17; 30(7): 1951–1956. doi:10.1021/acs.bioconjchem.9b00360.

Biomimetic Strategies To Treat Traumatic Brain Injury by Leveraging Fibrinogen

Ashley C. Brown^{*,†,‡}, Erin Lavik^{*,§}, Sarah E. Stabenfeldt^{*,||}

[†]Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Raleigh, North Carolina 27695, United States

[‡]Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina 27695, United States

[§]Chemical, Biochemical, and Environmental Engineering, University of Maryland, Baltimore County, Baltimore, Maryland 21250, United States

^{||}School of Biological and Health Systems Engineering, Arizona State University, Tempe, Arizona 85287, United States

Abstract

There were over 27 million new cases of traumatic brain injuries (TBIs) in 2016 across the globe. TBIs are often part of complicated trauma scenarios and may not be diagnosed initially because the primary clinical focus is on stabilizing the patient. Interventions used to stabilize trauma patients may inadvertently impact the outcomes of TBIs. Recently, there has been a strong interest in the trauma community toward administering fibrinogen-containing solutions intravenously to help stabilize trauma patients. While this interventional shift may benefit general trauma scenarios, fibrinogen is associated with potentially deleterious effects for TBIs. Here, we deconstruct what components of fibrinogen may be beneficial as well as potentially harmful following TBI and extrapolate this to biomimetic approaches to treat bleeding and trauma that may also lead to better outcomes following TBI.

Graphical Abstract

^{*}Corresponding Authors: aecarso2@ncsu.edu., elavik@umbc.edu., sarah.stabenfeldt@asu.edu.

The authors declare no competing financial interest.

TRAUMATIC BRAIN INJURY AND BREAKDOWN OF THE BLOOD BRAIN BARRIER

Traumatic brain injury (TBI) is one of the most common neurologic disorders and a leading cause of disability affecting patient function and quality of life.^{1,2} Most recent global estimates of the incidence and prevalence of TBI indicate that in 2016 alone there were over 27 million new cases of TBI with an age-standardized prevalence of TBI at 369 per 100 000 population (increase by 8.4% from 1990 to 2016).² Most concerning is that to date, despite promising preclinical data,³ no new pharmacological strategies have demonstrated improved patient outcomes in a phase III clinical trial. A TBI is defined as a mechanical insult that initiates immediate cellular death (i.e., primary injury) and stimulates a broad range of complex deleterious signaling cascades (i.e., secondary injury). In particular, the traumatic insult initiates the breakdown of the blood–brain barrier (BBB) and the influx of plasma proteins and cytokines into the parenchyma that contributes to activation of both local and systemic inflammatory players.

The BBB disruption after TBI may lead to extravasation of blood components into the brain parenchyma. Studies in different TBI animal models have demonstrated acute and delayed BBB disruption followed by restoration as evidenced by extravasation of standard molecules, such as endogenous serum immunoglobulins (IgG)^{4,5} and/or intravenously injected small molecule tracers, including Evans Blue and horseradish peroxidase (HRP).^{4,5} For example, previous studies with focal injury models (controlled cortical impact; CCI) established the BBB disruption as indicated by the extravasation of HRP⁶ or Evans Blue^{7,8} postinjury. Specifically, the BBB was compromised immediately after injury and remained significantly permeable for 5–7 days postinjury within the injury penumbra (with a second peak at ~3 days).^{6,8} Similarly, Schmidt et al. demonstrated that BBB disruption displayed regional differences following diffuse midline fluid percussion injury (FPI) with prominent

HRP leakage in the cerebral cortex (proximal to injury hub) and corpus callosum.⁴ Collectively, these seminal studies support the notion that TBI disrupts the BBB, resulting in the extravasation of blood constituents into the normally impermeable brain parenchymal space. Moreover, our recent studies identify a size-dependent BBB permeability within the injury zone that enables nanotherapeutic delivery after TBI.^{9,10}

LEVERAGING THE POSITIVE EFFECTS OF FIBRINOGEN IN TRAUMA WHILE AVOIDING THE OFF-TARGET EFFECTS IN THE CNS

There has been a push in trauma research to move from infusing with saline to infusion of plasma or plasma products.^{11–14} Plasma or plasma products reduce vascular permeability in a number of trauma models and improve clinical outcomes including survival.^{15–17} However, there are safety challenges with plasma, including lot to lot variability and immune concerns, promoting the study of specific plasma components following trauma. Recent trauma studies including clinical trials have shown the presence of fibrinogen, either in plasma or as a single therapeutic component, reduces the need for transfusions and increases survival.^{18–23}

Fibrinogen is a glycoprotein found in plasma that is critical for hemostasis but is also linked to important roles in reducing endothelial dysfunction and vascular permeability.²⁴ Fibrinogen is thought to be critical in trauma and may reduce edema, yet in the TBI literature, fibrinogen is implicated in worse outcomes including neurodegeneration.^{25,26} The disruption of the BBB following TBI provides ample opportunity for fibrinogen to extravasate into the brain parenchyma. The representative immunostain images in Figure 1 show the prominent presence of fibrin and fibrinogen (fibrin(ogen)) up to 24 h postinjury in a mouse focal TBI model (controlled cortical impact; CCI; Figure 1).

The disconnect between the trauma and TBI disciplines is critical to understand because there could be unintended negative impacts to infusing fibrinogen-containing compounds. Additionally, by understanding the disconnect between the trauma and TBI communities, we may be able to develop new, more effective therapies that are suitable for trauma broadly and CNS trauma, in particular.

WHAT IS THE SOURCE OF THE DIFFERENCES BETWEEN THE TRAUMA AND CNS LITERATURE?

While the source of the differences between the trauma and CNS literature is multifactorial, a major contributor may come down to the complex structure of fibrinogen. Fibrinogen is composed of two identical chains connected by disulfide bonds. Each half consists of three polypeptide chains (α , β , and γ).^{27,28} Each of these chains, and in fact their subunits, plays important roles in the permeabilization and stabilization of vessels as well as inflammation and neural injury. The α , β , and γ chains are joined in the central domain of fibrinogen, which is found within the “E” region of the molecule (Figure 2). The “E” region is flanked on either side by the “D” regions.

The “E” and “D” regions correspond to degradation products resulting from proteolytic cleaving by plasmin. D-dimers also result from cleavage of polymerized fibrin. Following activation of the coagulation cascade, soluble fibrinogen is converted to an insoluble fibrin matrix via proteolytic cleavage by thrombin of the fibrinopeptides within the central domain. Release of the fibrinopeptides exposes active fibrin knob sites which facilitate polymerization via interaction with corresponding fibrin hole sites on the β and γ chains within the D regions on adjacent fibrin(ogen) molecules. The various proteolytic fragments, including the E fragments, D fragments, and fibrinopeptides, are known to influence inflammation and tissue repair outcomes.

ENDOTHELIAL PERMEABILIZATION AND FIBRINOGEN

The γ chain of fibrinogen is an important player in disruption of tight junctions and transport. A peptide from the γ chain of fibrinogen, known as $\gamma 3$ corresponding to amino acids 117–133 of the γ chain, reportedly promotes intracellular transport of nanoparticles across endothelial cells.²⁹ Fibrinogen has been shown to impact endothelial cell tight junctions through ICAM signaling which strongly suggests that the γ chain triggers the permeability.³⁰ The same group noted that it appeared to be fibrinogen and not fibrin that was involved in the vascular permeability.³⁰

However, the γ chain is not alone in promoting permeabilization. Work that has dissected the role of the different peptides involved in the fibrinogen structure has shown that the β polypeptide chain is responsible for endothelial permeabilization.^{27,31} However, a subunit of the β chain also stabilizes tight junctions of endothelial cells.^{32,33} This subunit, the fibrinopeptide B β 15–42, reduces vascular leakage and stabilizes endothelial cell junctions in vivo.³⁴ This peptide is known as FX06 and has been studied in clinical trials.^{35–37}

Finally, the α chain interacts with the Sdc1 and promotes tight junction formation following trauma.²⁴ So parts of fibrinogen promote permeabilization of vessels, and parts promote stabilization and reduce leakiness. Depending on the state of coagulation and ratio of fibrinogen to fibrin polymerization, different parts of the chains will be more available for permeabilization.²⁷ This complexity may explain, in part, some of the differences between the observations in the trauma field and those regarding CNS injury.

INFLAMMATION AND FIBRINOGEN

At sites of BBB disruption, fibrinogen converts to fibrin which releases reactive oxygen species via triggered M1-like activation of macrophages and microglia.^{38,39} While fibrinogen is not proinflammatory, fibrin is.³⁸ The cleavage of fibrinogen exposes part of the γ chain that can bind with the CD11b/CD18 integrin on a number of cells and triggers the M1 phenotype in macrophages and microglia even in the absence of an injury.³⁹ In this particular study, fibrinogen from plasma or recombinant fibrinogen triggered inflammation and demyelination, but a fibrinogen derived from transgenic mice that produce a mutated γ chain that does not bind the CD11b/CD18 receptor showed far less inflammation and demyelination. The exciting thing is that when the binding region to CD11b/CD18 is either absent or blocked with an inhibitor, the inflammation and demyelination are not observed.³⁹

In fact, most of the neuroinflammatory responses to fibrin are associated with the activation of the CD11b/CD18 receptor, and inhibitors of this interaction significantly reduce inflammation and degeneration associated with a range of disease and injury models including TBI, Alzheimer's disease, and multiple sclerosis (MS).⁴⁰ Additionally, Schachtrup et al. recently demonstrated that fibrinogen is a courier for latent transforming growth factor- β protein (TGF- β) that ultimately stimulated reactive astrogliosis via the active TGF- β pathway.⁴¹ Thus, if one is able to engineer a version of fibrinogen without the reactive portions of the γ chain, one may be able to leverage the positive impacts of fibrinogen without the inflammatory component.

FIBRINOGEN AND NEURAL INHIBITION

Fibrinogen inhibits neurite outgrowth⁴² via interaction with $\beta 3$ receptor on neurons, and it inhibits remyelination by oligodendrocytes.⁴³ However, using ANCROD which cleaves only fibrinopeptide A⁴⁴ from fibrinogen leads to remyelination in the same injury model.⁴³ It is possible that fibrinogen has negative impacts on CNS tissue beyond the issues of permeability and inflammation. However, one of the challenges in the literature is that some treat fibrin and fibrinogen interchangeably⁴⁵ when they have very different structures, roles, and impacts on tissue in general and the CNS in particular. This is, in part, a function of groups using antibodies that react with both fibrin and fibrinogen in the brain.⁴⁶ By developing materials that allow us to probe the peptides associated with the fibrinogen chains, we will be able to determine the impact of the different peptides on both the vascular and neural components of the CNS.

SYNTHETIC MIMICS OF FIBRINOGEN FOR TRAUMA

Much of the work utilizing biomimetic strategies involving fibrinogen look at using the whole molecule as a template for building new tissue models.^{24,47,48} There is great logic in this approach. Fibrinogen presents a number of binding sites for cells to attach, and fibrin(ogen) plays important roles in signaling events for tissue repair.^{48,49} While there are fewer biomimetics of fibrinogen for hemostats, those that exist are quite exciting.

One of the best recent reviews of intravenous hemostats was by Dr. Pun's group;⁵⁰ we summarize a few examples here. Fibrinogen coated albumin particles reduced bleeding in thrombocytopenic rabbits⁵¹ but were large (3.5–4.5 μ m in diameter) leading to accumulation in the capillary beds of the lungs⁵² motivating development of smaller particles. In recent years, fibrinogen-coated nanoparticles have shown promise in thrombocytopenic models.⁵³ Interestingly, fibrinogen-based nanoparticles have also shown interest for delivering drugs to tumors since there are receptors in many cancers for components of fibrinogen^{54,55} and for delivery of growth factors to promote dermal wound healing.⁵⁶

Since the different regions of fibrinogen may have either beneficial or adverse impacts in TBI, it is exciting that a number of biomimetics have looked at using peptides drawn from fibrinogen. Liposomes carrying the fibrinogen γ chain dodecapeptide (HHLGGAKQAGDV), located on amino acids 400–411 of the γ chain, reduced bleeding in thrombocytopenic rats and rabbits compared with saline.^{57,58} A variant of these particles

also delivers adenosine diphosphate (ADP) which activates more platelets and has a rapid hemostatic response.^{59,60} While these molecules are exciting, the presence of the dodecapeptide from the γ chain might be less than ideal for TBI since it may promote breakdown of the BBB. Liposomes with multiple targeting ligands for the glycoprotein IIb/IIIa receptor as well as von Willibrand factor have been pursued as well.⁶¹ Using longer peptides and more peptides increases the complexity of the design and may exhibit off-target effects.

For TBI, it seems wise to avoid peptides associated with permeabilizing vessels such as those associated with the γ chain and parts of the β chain. One approach is to focus on the RGD peptide from the α -chain. While RGD is ubiquitous throughout the body, the GPIIa/IIIb receptor on activated platelets has a tremendously high affinity for the RGD peptide and rapidly binds upon platelet activation.^{62–65} Polyester nanoparticles functionalized with RGD have been shown to reduce bleeding in a number of models^{66,67} and are associated with better neurological outcomes following blast-induced brain injury.⁶⁸ Ultimately, pursuing an approach that leverages the potential of fibrinogen but excludes the potentially problematic regions may be wise.

However, perhaps the wiser approach is to avoid the issues surrounding fibrinogen-mimics and look at alternative synthetic hemostats. Hydrogel particles with antibody fragments have shown promise in models of bleeding.⁶⁹ These particles are highly deformable and over time deform fibrin matrices to mimic the platelet response of clot retraction.

CONCLUSIONS AND OUTLOOKS

Fibrinogen looks incredibly promising for treating trauma, but with TBI being involved in a large fraction of traumas, there are concerns about the potential for fibrinogen to exacerbate neurological outcomes. Bioconjugate approaches may be able to address the shortcomings of broad fibrinogen strategies by maximizing the benefits of specific molecular subunits while mitigating the risks. It is essential to understand the complexities and intricacies of trauma, coagulation, and neural injury to then apply that understanding to develop new fibrinogen-mimetic bioconjugate systems appropriate for all trauma scenarios.

ACKNOWLEDGMENTS

Dr. Vimala Bharadwaj and Alisha Kodibagkar are acknowledged for their technical assistance in generating the fibrinogen IHC image. Amanda Witten is acknowledged for creating the graphical abstract figure. The authors also acknowledge the following funding sources: NIH NIAMS (Grant R21AR071017; A.C.B.), NSF CAREER DMR (Grant 1847488; A.C.B.), NIH NINDS (Grant R56NS100732; E.L.), NIH NICHD (Grant DP2HD084067; S.E.S.), and NSF CAREER CBET (Grant 1454282; S.E.S.).

REFERENCES

- (1). Faul M, Xu L, Wald MM, and Coronado VG (2010) Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations, and Deaths, Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta, GA.
- (2). GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. (2019) Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* 18, 56–87. [PubMed: 30497965]

- (3). Xiong Y, Mahmood A, and Chopp M (2009) Emerging treatments for traumatic brain injury. *Expert Opin. Emerging Drugs* 14, 67–84.
- (4). Schmidt RH, and Grady MS (1993) Regional patterns of blood-brain barrier breakdown following central and lateral fluid percussion injury in rodents. *J. Neurotrauma* 10, 415–30. [PubMed: 8145265]
- (5). Tanno H, Nockels RP, Pitts LH, and Noble LJ (1992) Breakdown of the blood-brain barrier after fluid percussive brain injury in the rat. Part 1: Distribution and time course of protein extravasation. *J. Neurotrauma* 9, 21–32. [PubMed: 1619673]
- (6). Baldwin SA, Fugaccia I, Brown DR, Brown LV, and Scheff SW (1996) Blood-brain barrier breach following cortical contusion in the rat. *J. Neurosurg* 85, 476–81. [PubMed: 8751635]
- (7). Adelson PD, Whalen MJ, Kochanek PM, Robichaud P, and Carlos TM (1998) Blood brain barrier permeability and acute inflammation in two models of traumatic brain injury in the immature rat: a preliminary report. *Acta Neurochir Suppl* 71, 104–6. [PubMed: 9779157]
- (8). Baskaya MK, Rao AM, Dogan A, Donaldson D, and Dempsey RJ (1997) The biphasic opening of the blood-brain barrier in the cortex and hippocampus after traumatic brain injury in rats. *Neurosci. Lett* 226, 33–6. [PubMed: 9153635]
- (9). Bharadwaj VN, Lifshitz J, Adelson PD, Kodibagkar VD, and Stabenfeldt SE (2016) Temporal assessment of nanoparticle accumulation after experimental brain injury: Effect of particle size. *Sci. Rep* 6, 29988. [PubMed: 27444615]
- (10). Bharadwaj VN, Rowe RK, Harrison J, Wu C, Anderson TR, Lifshitz J, Adelson PD, Kodibagkar VD, and Stabenfeldt SE (2018) Blood-brain barrier disruption dictates nanoparticle accumulation following experimental brain injury. *Nanomedicine* 14, 2155–2166. [PubMed: 29933022]
- (11). Rowell SE, Fair KA, Barbosa RR, Watters JM, Bulger EM, Holcomb JB, Cohen MJ, Rahbar MH, Fox EE, and Schreiber MA (2016) The Impact of Pre-Hospital Administration of Lactated Ringer's Solution versus Normal Saline in Patients with Traumatic Brain Injury. *J. Neurotrauma* 33, 1054–9. [PubMed: 26914721]
- (12). Watts S, Nordmann G, Brohi K, Midwinter M, Woolley T, Gwyther R, Wilson C, Poon H, and Kirkman E (2015) Evaluation of Prehospital Blood Products to Attenuate Acute Coagulopathy of Trauma in a Model of Severe Injury and Shock in Anesthetized Pigs. *Shock* 44 (Suppl. 1), 138–48. [PubMed: 26177017]
- (13). Winstedt D, Thomas OD, Nilsson F, Olanders K, and Schött U (2014) Correction of hypothermic and dilutional coagulopathy with concentrates of fibrinogen and factor XIII: an in vitro study with ROTEM. *Scan. J. Trauma, Resusc. Emerg. Med* 22, 73.
- (14). Hess JR, and Holcomb JB (2008) Transfusion practice in military trauma. *Transfusion medicine (Oxford, England)* 18, 143–50.
- (15). Wataha K, Menge T, Deng X, Shah A, Bode A, Holcomb JB, Potter D, Kozar R, Spinella PC, and Pati S (2013) Spray-dried plasma and fresh frozen plasma modulate permeability and inflammation in vitro in vascular endothelial cells. *Transfusion* 53, 80S–90S. [PubMed: 23301978]
- (16). Potter DR, Baimukanova G, Keating SM, Deng X, Chu JA, Gibb SL, Peng Z, Muench MO, Fomin ME, Spinella PC, et al. (2015) Fresh frozen plasma and spray-dried plasma mitigate pulmonary vascular permeability and inflammation in hemorrhagic shock. *J. Trauma Acute Care Surg* 78, S7–S17. [PubMed: 26002267]
- (17). Kozar RA, and Pati S (2015) Syndecan-1 restitution by plasma after hemorrhagic shock. *J. Trauma Acute Care Surg* 78, S83–6. [PubMed: 26002270]
- (18). Spahn DR, Spahn GH, and Stein P (2016) Indications and Risks of Fibrinogen in Surgery and Trauma. *Semin. Thromb. Hemostasis* 42, 147–54.
- (19). Rourke C, Curry N, Khan S, Taylor R, Raza I, Davenport R, Stanworth S, and Brohi K (2012) Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. *J. Thromb. Haemostasis* 10, 1342–51. [PubMed: 22519961]
- (20). Levy JH, Welsby I, and Goodnough LT (2014) Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. *Transfusion* 54, 1389–405 (quiz 1388). [PubMed: 24117955]

- (21). Kozek-Langenecker S, Sorensen B, Hess JR, and Spahn DR (2011) Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. *Crit Care* 15, R239. [PubMed: 21999308]
- (22). Innerhofer P, Fries D, Mittermayr M, Innerhofer N, von Langen D, Hell T, Gruber G, Schmid S, Friesenecker B, Lorenz IH, et al. (2017) Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. *Lancet. Haematology* 4, e258–e271. [PubMed: 28457980]
- (23). Floccard B, Rugeri L, Faure A, Saint Denis M, Boyle EM, Peguet O, Levrat A, Guillaume C, Marcotte G, Vulliez A, et al. (2012) Early coagulopathy in trauma patients: an on-scene and hospital admission study. *Injury* 43, 26–32. [PubMed: 21112053]
- (24). Wu F, Pati S, and Kozar R (2016) Fibrinogen contributes to stabilization of cell surface Syndecan-1: A novel mechanism for endothelial protection by plasma. *Shock* 45, 116.
- (25). Muradashvili N, and Lominadze D (2013) Role of fibrinogen in cerebrovascular dysfunction after traumatic brain injury. *Brain Inj* 27, 1508–15. [PubMed: 24063686]
- (26). Muradashvili N, Benton RL, Saatman KE, Tyagi SC, and Lominadze D (2015) Ablation of matrix metalloproteinase-9 gene decreases cerebrovascular permeability and fibrinogen deposition post traumatic brain injury in mice. *Metab. Brain Dis* 30, 411–26. [PubMed: 24771110]
- (27). Mosesson MW (2005) Fibrinogen and fibrin structure and functions. *J. Thromb. Haemostasis* 3, 1894–904. [PubMed: 16102057]
- (28). Brown AC, and Barker TH (2014) Fibrin-based biomaterials: modulation of macroscopic properties through rational design at the molecular level. *Acta Biomater.* 10, 1502–14. [PubMed: 24056097]
- (29). Garnacho C, Serrano D, and Muro S (2012) A fibrinogen-derived peptide provides intercellular adhesion molecule-1-specific targeting and intraendothelial transport of polymer nanocarriers in human cell cultures and mice. *J. Pharmacol. Exp. Ther* 340, 638–47. [PubMed: 22160267]
- (30). Patibandla PK, Tyagi N, Dean WL, Tyagi SC, Roberts AM, and Lominadze D (2009) Fibrinogen induces alterations of endothelial cell tight junction proteins. *J. Cell. Physiol* 221, 195–203. [PubMed: 19507189]
- (31). Sahni A, Arevalo MT, Sahni SK, and Simpson-Haidaris PJ (2009) The VE-cadherin binding domain of fibrinogen induces endothelial barrier permeability and enhances transendothelial migration of malignant breast epithelial cells. *Int. J. Cancer* 125, 577–84. [PubMed: 19358279]
- (32). Groger M, Pasteiner W, Ignatyev G, Matt U, Knapp S, Atrasheuskaya A, Bukin E, Friedl P, Zinkl D, Hofer-Warbinek R, et al. (2009) Peptide Bbeta(15–42) preserves endothelial barrier function in shock. *PLoS One* 4, e5391. [PubMed: 19401765]
- (33). Bergt S, Gruenewald M, Beltschany C, Grub A, Neumann T, Albrecht M, Vollmar B, Zacharowski K, Roesner JP, and Meybohm P (2016) The Fibrin-Derived Peptide Bbeta15–42 (FX06) Ameliorates Vascular Leakage and Improves Survival and Neurocognitive Recovery: Implications From Two Animal Models of Cardiopulmonary Resuscitation. *Crit. Care Med* 44, e988–95. [PubMed: 27322362]
- (34). Urbschat A, Rupprecht K, Zacharowski K, Obermuller N, Scheller B, Holfeld J, Tepekoylu C, Hofmann R, and Paulus P (2015) Combined peri-ischemic administration of Bbeta15–42 in treating ischemia reperfusion injury of the mouse kidney. *Microvasc. Res* 101, 48–54. [PubMed: 26116861]
- (35). Hallen J, Atar D, and Serebruany V (2014) Effects of FX06 in vitro on platelet, coagulation, and fibrinolytic biomarkers in volunteers and patients with documented coronary artery disease. *American journal of therapeutics* 21, 91–8. [PubMed: 19770797]
- (36). Beishuizen A, and Girbes AR (2009) Hemorrhagic shock and reperfusion injury: the critical interplay of fibrin fragments, leukocytes, and vascular endothelial-cadherin. *Crit. Care Med* 37, 771–2. [PubMed: 19325382]
- (37). Atar D, Huber K, Rupprecht HJ, Kopecky SL, Schwitter J, Theek C, Brandl K, Henning R, and Geudelin B (2007) Rationale and design of the ‘F.I.R.E.’ study. A multicenter, double-blind, randomized, placebo-controlled study to measure the effect of FX06 (a fibrin-derived peptide Bbeta(15–42)) on ischemia-reperfusion injury in patients with acute myocardial infarction

undergoing primary percutaneous coronary intervention. *Cardiology* 108, 117–23. [PubMed: 17019083]

- (38). Davalos D, and Akassoglou K (2012) Fibrinogen as a key regulator of inflammation in disease. *Semin. Immunopathol* 34, 43–62. [PubMed: 22037947]
- (39). Ryu JK, Petersen MA, Murray SG, Baeten KM, Meyer-Franke A, Chan JP, Vagena E, Bedard C, Machado MR, Rios Coronado PE, et al. (2015) Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. *Nat. Commun* 6, 8164. [PubMed: 26353940]
- (40). Petersen MA, Ryu JK, and Akassoglou K (2018) Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. *Nat. Rev. Neurosci* 19, 283–301. [PubMed: 29618808]
- (41). Schachtrup C, Ryu JK, Helmrick MJ, Vagena E, Galanakis DK, Degen JL, Margolis RU, and Akassoglou K (2010) Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage. *J. Neurosci* 30, 5843–54. [PubMed: 20427645]
- (42). Schachtrup C, Lu P, Jones LL, Lee JK, Lu J, Sachs BD, Zheng B, and Akassoglou K (2007) Fibrinogen inhibits neurite outgrowth via beta 3 integrin-mediated phosphorylation of the EGF receptor. *Proc. Natl. Acad. Sci. U. S. A* 104, 11814–9. [PubMed: 17606926]
- (43). Petersen MA, Ryu JK, Chang KJ, Etxeberria A, Bardehle S, Mendiola AS, Kamau-Devers W, Fancy SPJ, Thor A, Bushong EA, et al. (2017) Fibrinogen Activates BMP Signaling in Oligodendrocyte Progenitor Cells and Inhibits Remyelination after Vascular Damage. *Neuron* 96, 1003–1012. [PubMed: 29103804]
- (44). Liu S, Marder VJ, Levy DE, Wang SJ, Yang F, Paganini-Hill A, and Fisher MJ (2011) Ancrod and fibrin formation: perspectives on mechanisms of action. *Stroke* 42, 3277–80. [PubMed: 21868728]
- (45). Bardehle S, Rafalski VA, and Akassoglou K (2015) Breaking boundaries-coagulation and fibrinolysis at the neurovascular interface. *Front. Cell. Neurosci* 9, 354. [PubMed: 26441525]
- (46). Cortes-Canteli M, Mattei L, Richards AT, Norris EH, and Strickland S (2015) Fibrin deposited in the Alzheimer's disease brain promotes neuronal degeneration. *Neurobiol. Aging* 36, 608–17. [PubMed: 25475538]
- (47). Dikovsky D, Bianco-Peled H, and Seliktar D (2006) The effect of structural alterations of PEG-fibrinogen hydrogel scaffolds on 3-D cellular morphology and cellular migration. *Biomaterials* 27, 1496–506. [PubMed: 16243393]
- (48). Mironi-Harpaz I, Berdichevski A, and Seliktar D (2014) Fabrication of PEGylated fibrinogen: a versatile injectable hydrogel biomaterial. *Methods Mol. Biol* 1181, 61–8. [PubMed: 25070327]
- (49). Pradhan S, Hassani I, Seeto WJ, and Lipke EA (2017) PEG-fibrinogen hydrogels for three-dimensional breast cancer cell culture. *J. Biomed. Mater. Res., Part A* 105, 236–252.
- (50). Chan LW, White NJ, and Pun SH (2015) Synthetic Strategies for Engineering Intravenous Hemostats. *Bioconjugate Chem.* 26, 1224–36.
- (51). Levi M, Friederich PW, Middleton S, Groot P. G. d., Wu YP, Harris R, Biemond BJ, Heijnen HFG, Levin J, Cate J. W. t., et al. (1999) Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. *Nat. Med* 5, 107–111. [PubMed: 9883848]
- (52). Ilium L, Davis SS, Wilson CG, Thomas NW, Frier M, and Hardy JG (1982) Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape. *Int. J. Pharm* 12, 135–146.
- (53). Sung AD, Yen R, Deoliveira D, Jiao Y, Piryani S, Bernanke A, Hall S, Klemp K, Yun S, Arepally G, et al. (2015) Fibrinogen-Coated Nanospheres Prevent Thrombocytopenia-Related Bleeding. *Biol. Blood Marrow Transplant* 21, S111–S113.
- (54). Rejinold NS, Baby T, Chennazhi KP, and Jayakumar R (2014) Dual drug encapsulated thermo-sensitive fibrinogen-graft-poly (N-isopropyl acrylamide) nanogels for breast cancer therapy. *Colloids Surf., B* 114, 209–217.
- (55). Rejinold NS, Muthunarayanan M, Deepa N, Chennazhi K, Nair S, and Jayakumar R (2010) Development of novel fibrinogen nanoparticles by two-step co-acervation method. *Int. J. Biol. Macromol* 47, 37–43. [PubMed: 20380849]

- (56). Muhamed I, Sproul EP, Ligler FS, and Brown AC (2019) Fibrin Nanoparticles Coupled with Keratinocyte Growth Factor Enhance the Dermal Wound-Healing Rate. *ACS Appl. Mater. Interfaces* 11, 3771–3780. [PubMed: 30604611]
- (57). Okamura Y, Takeoka S, Eto K, Maekawa I, Fujie T, Maruyama H, Ikeda Y, and Handa M (2009) Development of fibrinogen γ -chain peptide-coated, adenosine diphosphate-encapsulated liposomes as a synthetic platelet substitute. *J. Thromb. Haemostasis* 7, 470–477. [PubMed: 19143920]
- (58). Okamura Y, Takeoka S, Teramura Y, Maruyama H, Tsuchida E, Handa M, and Ikeda Y (2005) Hemostatic effects of fibrinogen γ -chain dodecapeptide-conjugated polymerized albumin particles in vitro and in vivo. *Transfusion* 45, 1221–1228. [PubMed: 15987370]
- (59). Nishikawa K, Hagsawa K, Kinoshita M, Shono S, Katsuno S, Doi M, Yanagawa R, Suzuki H, Iwaya K, Saitoh D, et al. (2012) Fibrinogen gamma-chain peptide-coated, ADP-encapsulated liposomes rescue thrombocytopenic rabbits from non-compressible liver hemorrhage. *J. Thromb. Haemostasis* 10, 2137–2148. [PubMed: 22905905]
- (60). Hagsawa K, Nishikawa K, Yanagawa R, Kinoshita M, Doi M, Suzuki H, Iwaya K, Saitoh D, Seki S, Takeoka S, Handa M, and Nishida Y (2015) Treatment with fibrinogen γ -chain peptide-coated, adenosine 5'-diphosphate-encapsulated liposomes as an infusible hemostatic agent against active liver bleeding in rabbits with acute thrombocytopenia. *Transfusion* 55, 314–25. [PubMed: 25145766]
- (61). Modery-Pawlowski CL, Tian LL, Ravikumar M, Wong TL, and Sen Gupta A (2013) In vitro and in vivo hemostatic capabilities of a functionally integrated platelet-mimetic liposomal nanoconstruct. *Biomaterials* 34, 3031–41. [PubMed: 23357371]
- (62). Tomiyama Y, Tsubakio T, Piotrowicz RS, Kurata Y, Loftus JC, and Kunicki TJ (1992) The Arg-Gly-Asp (RGD) recognition site of platelet glycoprotein IIb-IIIa on nonactivated platelets is accessible to high-affinity macromolecules. *Blood* 79, 2303–12. [PubMed: 1373972]
- (63). Collier BS, Kutok JL, Scudder LE, Galanakis DK, West SM, Rudomen GS, and Springer KT (1993) Studies of activated GPIIb/IIIa receptors on the luminal surface of adherent platelets. Paradoxical loss of luminal receptors when platelets adhere to high density fibrinogen. *J. Clin. Invest* 92, 2796–806. [PubMed: 8254034]
- (64). Mohri H, and Ohkubo T (1994) “Bridged” peptide of fibrinogen binds to platelets activated by RGD peptide as well as by ADP. *Peptides* 15, 683–7. [PubMed: 7937346]
- (65). Bennett JS (2001) Platelet-fibrinogen interactions. *Ann. N. Y. Acad. Sci* 936, 340–54. [PubMed: 11460491]
- (66). Onwukwe C, Maisha N, Holland M, Varley M, Groynom R, Hickman D, Uppal N, Shoffstall A, Ustin J, and Lavik E (2018) Engineering Intravenously Administered Nanoparticles to Reduce Infusion Reaction and Stop Bleeding in a Large Animal Model of Trauma. *Bioconjugate Chem.* 29, 2436–2447.
- (67). Shoffstall AJ, Everhart LM, Varley ME, Soehnlén ES, Shick AM, Ustin JS, and Lavik EB (2013) Tuning ligand density on intravenous hemostatic nanoparticles dramatically increases survival following blunt trauma. *Biomacromolecules* 14, 2790–7. [PubMed: 23841817]
- (68). Hubbard WB, Lashof-Sullivan M, Greenberg S, Norris C, Eck J, Lavik E, and VandeVord P (2018) Hemostatic nanoparticles increase survival, mitigate neuropathology and alleviate anxiety in a rodent blast trauma model. *Sci. Rep* 8, 10622. [PubMed: 30006635]
- (69). Brown AC, Stabenfeldt SE, Ahn B, Hannan RT, Dhada KS, Herman ES, Stefanelli V, Guzzetta N, Alexeev A, Lam WA, et al. (2014) Ultrasoft microgels displaying emergent platelet-like behaviours. *Nat. Mater* 13, 1108–14. [PubMed: 25194701]

Figure 1. Fibrin(ogen) deposition post-TBI. Representative time-course immunohistochemistry images with anti-fibrin(ogen) antibody in mouse brain tissue sections following CCI (HRP secondary antibody followed by DAB chromogenic substrate). Regions of positive fibrin(ogen) were observed in the brain parenchyma out to 24 h postinjury as indicated with the dark brown stain highlighted with white arrows: regions of positive fibrin(ogen) compared to control contralateral tissue. Scale bars = 1 mm.

Figure 2.

Fibrinogen structure. A α chains are shown in blue, B β chains are shown in green, and γ chains are shown in red. Interchain disulfide bridges connecting the six polypeptide chains in the central domain are shown in orange, and disulfide rings stabilizing the coiled-coil regions are shown in yellow. Reproduced with permission from *Acta Biomaterialia* (Brown and Barker 2014), Copyright 2014 Elsevier.²⁸